Outcome of patients with hepatocellular carcinoma listed for liver transplantation within the Eurotransplant allocation system.

PubWeight™: 0.82‹?›

🔗 View Article (PMID 18383082)

Published in Liver Transpl on April 01, 2008

Authors

Michael Adler1, Filip De Pauw, Pierre Vereerstraeten, Agnese Fancello, Jan Lerut, Peter Starkel, Hans Van Vlierberghe, Roberto Troisi, Vincent Donckier, Olivier Detry, Jean Delwaide, Peter Michielsen, Thierry Chapelle, Jacques Pirenne, Frederik Nevens

Author Affiliations

1: Medico-Surgical Department of Gastroenterology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium. michael.adler@erasme.ulb.ac.be

Articles by these authors

Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48

Early liver transplantation for severe alcoholic hepatitis. N Engl J Med (2011) 8.50

Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med (2010) 8.40

A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93

Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med (2009) 5.26

Intrarenal resistive index after renal transplantation. N Engl J Med (2013) 4.19

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol (2012) 3.88

Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med (2010) 3.84

Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology (2014) 3.23

Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. J Hepatol (2013) 2.98

Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut (2010) 2.91

Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology (2013) 2.84

Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest (2008) 2.73

Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology (2013) 2.64

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology (2002) 2.54

Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transpl Int (2013) 2.53

Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology (2012) 2.49

Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol (2006) 2.47

Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology (2012) 2.46

Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest (2011) 2.36

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2009) 2.33

Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med (2004) 2.29

Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell (2010) 2.26

Machine perfusion versus cold storage for preservation of kidneys from expanded criteria donors after brain death. Transpl Int (2011) 2.25

Body surface area and body weight predict total liver volume in Western adults. Liver Transpl (2002) 2.21

Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol (2012) 2.15

Laparoscopic live donor right nephrectomy: a new technique to maximize the length of the renal vein using a modified Endo GIA stapler. Eur Urol (2006) 2.14

Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome. Radiology (2013) 2.12

Organized proteomic heterogeneity in colorectal cancer liver metastases and implications for therapies. Hepatology (2013) 2.10

Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut (2013) 2.10

Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl (2013) 2.09

Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08

Endoscopic resection of ampullary lesions: a single-center 8-year retrospective cohort study of 91 patients with long-term follow-up. Surg Endosc (2013) 2.01

Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl (2003) 2.01

Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg (2013) 1.98

3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet (2006) 1.97

Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology (2007) 1.95

Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology (2013) 1.93

Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol (2009) 1.79

Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl (2002) 1.79

Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg (2004) 1.79

A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology (2003) 1.73

Congenital veno-venous malformations of the liver: widely variable clinical presentations. J Gastroenterol Hepatol (2007) 1.68

Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol (2002) 1.66

Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gastroenterology (2013) 1.66

Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology (2011) 1.65

Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut (2012) 1.63

Progression rate of Chinese herb nephropathy: impact of Aristolochia fangchi ingested dose. Nephrol Dial Transplant (2002) 1.62

The histology of kidney transplant failure: a long-term follow-up study. Transplantation (2014) 1.61

Open intraperitoneal versus retromuscular mesh repair for umbilical hernias less than 3 cm diameter. Am J Surg (2010) 1.60

A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis. Hepatology (2005) 1.59

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59

HLA mismatches remain risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with anti-interleukin-2 receptor antibodies. Transplantation (2008) 1.58

Outcome of the living kidney donor. Nephrol Dial Transplant (2012) 1.57

Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion. Liver Transpl (2006) 1.57

Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study. J Hepatol (2013) 1.57

Pathophysiology and prevention of postoperative peritoneal adhesions. World J Gastroenterol (2011) 1.54

Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J Hepatol (2006) 1.54

The spectrum of nonadherence with medication in heart, liver, and lung transplant patients assessed in various ways. Transpl Int (2011) 1.53

188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. J Nucl Med (2005) 1.52

Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients. Liver Transpl (2005) 1.52

Intra-arterial treatment with ⁹⁰Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital. Eur J Nucl Med Mol Imaging (2011) 1.50

Alteration of protein glycosylation in liver diseases. J Hepatol (2008) 1.47

Troponin I is a predictor of acute cardiac events in the immediate postoperative renal transplant period. Transplantation (2010) 1.45

Aminopyrine breath test compared to the MELD and Child-Pugh scores for predicting mortality among cirrhotic patients awaiting liver transplantation. Transpl Int (2003) 1.44

Noncirrhotic presinusoidal portal hypertension is common in cystic fibrosis-associated liver disease. Hepatology (2011) 1.43

Liver transplantation for nonsteroidal anti-inflammatory drug-induced liver failure: nimesulide as the first implicated compound. Eur J Gastroenterol Hepatol (2007) 1.42

Liver transplantation for unresectable hepatocellular carcinoma in normal livers. J Hepatol (2012) 1.42

Lipid peroxidation products in machine perfusion of older donor kidneys. J Surg Res (2012) 1.42

Angiogenesis in chronic liver disease and its complications. Liver Int (2010) 1.41

Echocardiography for the detection of portopulmonary hypertension in liver transplant candidates: an analysis of cutoff values. Liver Transpl (2013) 1.41

The extent of vacuolation in non-heart-beating porcine donor liver grafts prior to transplantation predicts their viability. Liver Transpl (2008) 1.41

GC-MS analysis of breath odor compounds in liver patients. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.40

Liver segmentation in living liver transplant donors: comparison of semiautomatic and manual methods. Radiology (2004) 1.39

Pretransplant predictors of posttransplant adherence and clinical outcome: an evidence base for pretransplant psychosocial screening. Transplantation (2009) 1.38

Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol (2012) 1.35

Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol (2006) 1.32

Duffy and Kidd blood group antigens: minor histocompatibility antigens involved in renal allograft rejection? Transfusion (2007) 1.31

Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver Int (2011) 1.30

Effects of hemi-portocaval shunts for inflow modulation on the outcome of small-for-size grafts in living donor liver transplantation. Am J Transplant (2005) 1.26

Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med (2012) 1.26

Modulation of portal graft inflow: a necessity in adult living-donor liver transplantation? Ann Surg (2003) 1.26

Thiamine status in humans and content of phosphorylated thiamine derivatives in biopsies and cultured cells. PLoS One (2010) 1.25